Research map: Zolbetuximab plus pembrolizumab and chemotherapy in CLDN18.2-positive, HER2-negative, PD-L1-positive gastric or gastroesophageal junction adenocarcinoma: randomized, double-blind, phase III LUCERNA trial

Back to the article

Papers in this map

  1. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial · Kohei Shitara · 2023 · 826 citations · Cited by this paper
  2. Early-onset biliary tract cancers: clinical and molecular insights · 2026 · Related
  3. Regulatory mechanisms of PD-1/PD-L1 in cancers · Xin Lin · 2024 · 775 citations · Cited by this paper
  4. Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer · 2026 · Related
  5. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial · Sun Young Rha · 2023 · 698 citations · Cited by this paper
  6. A prospective, multicenter, observational study of trastuzumab deruxtecan in elderly patients with HER2-positive gastric cancer: EN-COURAGE · 2026 · Related
  7. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial · Manish A. Shah · 2023 · 657 citations · Cited by this paper
  8. Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study · 2026 · Related
  9. Claudin 18.2 as a novel therapeutic target · Izuma Nakayama · 2024 · 206 citations · Cited by this paper
  10. Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study · 2026 · Related
  11. Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology · Jaffer A. Ajani · 2025 · 205 citations · Cited by this paper
  12. Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer · 2026 · Related
  13. A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer · Uğur Şahin · 2018 · 171 citations · Cited by this paper
  14. The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors · 2026 · Related
  15. Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma · Kohei Shitara · 2024 · 97 citations · Cited by this paper
  16. BevRam-GC01 study protocol: a phase I trial of bevacizumab plus ramucirumab and paclitaxel in advanced gastric cancer · 2026 · Related
  17. First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial · Kohei Shitara · 2026 · 16 citations · Cited by this paper
  18. Incidence, treatment variation, and survival of synchronous head and neck and esophageal carcinomas: a descriptive nationwide cohort study in the Netherlands · 2026 · Related
  19. 42P Antitumor activity of zolbetuximab combined with chemotherapy and anti-mouse PD-1 antibody (anti-mPD-1) in a syngeneic mouse model and a virtual preclinical trial using a quantitative systems pharmacology (QSP) model · T. Nakayama · 2022 · 7 citations · Cited by this paper
  20. Recent advances in loco-ablative therapies for liver cancers · 2026 · Related
  21. Prevalence of claudin 18.2 (CLDN18.2) and the association of biomarkers with clinical activity in patients with gastric or gastroesophageal adenocarcinoma (G/GEJa) treated with zolbetuximab. · Diarmuid Martin Moran · 2023 · 6 citations · Cited by this paper

Source: OpenAlex (CC0)